8-K: Aadi Bioscience Closes $100 Million Private Placement to Fund Operations into 2028

Aadi Bioscience secures $100 million in a private placement to advance its oncology therapeutics and extend its operational runway into 2028.

Summary

• Aadi Bioscience, Inc. closed a $100 million private placement (PIPE Financing) on March 4, 2025.
• The financing was led by Ally Bridge Group, with participation from new and existing investors.
• Aadi issued 21,592,000 shares of common stock at $2.40 per share.
• Pre-funded warrants to purchase up to 20,076,500 shares were sold at $2.3999 per warrant.
• The company intends to use the net proceeds to fund upfront payments under its license agreement with WuXi Biologics and for general corporate purposes.
• Combined with proceeds from the sale of its FYARRO business and existing cash, the financing is expected to fund operations into 2028, including anticipated clinical data readouts for its ADC portfolio.
• In connection with the private placement, Aadi entered into a registration rights agreement to register the resale of the shares of common stock sold in the private placement.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company successfully raised $100 million, extending its operational runway into 2028. However, there is some dilution for existing shareholders.

Positives

• The $100 million private placement provides Aadi Bioscience with significant capital to fund its operations.
• The financing extends the company's operational runway into 2028, allowing it to advance its ADC portfolio and achieve anticipated clinical data readouts.
• The participation of new and existing investors indicates confidence in Aadi's strategy and potential.
• The registration rights agreement provides liquidity for investors in the private placement.

Negatives

• The private placement dilutes existing shareholders' ownership due to the issuance of new shares.
• The company is reliant on the successful sale of its FYARRO business to achieve its projected cash runway.
• The company is reliant on the successful clinical data readouts for its ADC portfolio.

Risks

• The company's ability to successfully develop and commercialize its ADC portfolio is subject to clinical trial risks and regulatory approvals.
• The company's financial projections are based on certain assumptions, including the successful sale of FYARRO and the achievement of clinical milestones.
• The company is subject to market risks and macroeconomic conditions that could impact its ability to raise additional capital in the future.
• Failure to meet milestones could result in the need for additional capital raises.

Future Outlook

Aadi expects the proceeds from the private placement and the sale of its FYARRO business, along with existing cash, to fund operations into 2028, including anticipated clinical data readouts for its ADC portfolio.

Industry Context

The financing reflects continued investor interest in oncology therapeutics companies, particularly those focused on precision medicine and ADC technologies. Aadi's ability to attract new and existing investors in a challenging market environment underscores the perceived value of its pipeline and strategy.

Comparison to Industry Standards

• Comparable companies in the oncology space, such as Seagen (acquired by Pfizer) and Immunomedics (acquired by Gilead), have also utilized private placements to fund clinical development and commercialization efforts.
• The size of Aadi's private placement is within the typical range for similar stage companies in the biotech industry.
• The operational runway extended to 2028 provides Aadi with a competitive advantage in terms of financial stability and the ability to execute its long-term strategy.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Employees benefit from the extended operational runway, providing job security and opportunities for growth.
• Customers (patients) may benefit from the advancement of Aadi's ADC portfolio and the potential for improved cancer treatments.
• Suppliers and creditors benefit from Aadi's improved financial stability and ability to meet its obligations.

Next Steps

• Aadi intends to use the net proceeds from the private placement to fund certain upfront payments under its license agreement with WuXi Biologics and for working capital and other general corporate purposes.
• Aadi will file a registration statement with the SEC to register the resale of the shares of common stock sold in the private placement.
• Aadi will continue to advance its ADC portfolio and pursue anticipated clinical data readouts.

Key Dates

Keywords

Aadi Bioscience, private placement, PIPE financing, oncology, therapeutics, FYARRO, ADC portfolio, WuXi Biologics, registration rights, clinical data, Ally Bridge Group, OrbiMed, Invus, Kalehua Capital, Avoro Capital, KVP Capital, Acuta Capital Partners